StockNews.com Initiates Coverage on CEL-SCI (NYSE:CVM)

Stock analysts at StockNews.com assumed coverage on shares of CEL-SCI (NYSE:CVM) in a report issued on Thursday. The brokerage set a “sell” rating on the stock.

CEL-SCI Price Performance

Shares of NYSE CVM opened at $0.30 on Thursday. The stock has a market cap of $23.47 million, a PE ratio of -0.63 and a beta of 0.67. CEL-SCI has a fifty-two week low of $0.29 and a fifty-two week high of $2.39. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.09 and a current ratio of 1.07. The stock has a fifty day moving average of $0.39 and a 200-day moving average of $0.69.

Institutional Investors Weigh In On CEL-SCI

Several hedge funds have recently added to or reduced their stakes in CVM. Plotkin Financial Advisors LLC bought a new stake in CEL-SCI during the third quarter worth about $98,000. Thoroughbred Financial Services LLC lifted its stake in shares of CEL-SCI by 40.1% in the 4th quarter. Thoroughbred Financial Services LLC now owns 191,661 shares of the company’s stock valued at $76,000 after acquiring an additional 54,900 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of CEL-SCI by 9.6% in the 3rd quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock valued at $650,000 after acquiring an additional 53,879 shares during the last quarter. Institutional investors own 12.08% of the company’s stock.

CEL-SCI Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.